Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Saikosaponin-d suppresses cell growth in renal cell carcinoma through EGFR/p38 signaling pathway.
|
28485157 |
2019 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Real-time fluorescence quantitative PCR (qRT-PCR) was used to detect the expression of VEGF and EGFR in RCC tissues and paracancer tissues.
|
30358217 |
2019 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppressed OGT expression inhibits cell proliferation and modulates EGFR expression in renal cell carcinoma.
|
30962710 |
2019 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results revealed that CAV2 promotes the growth of renal cell carcinoma through EGFR/PI3K/Akt pathway.
|
30288056 |
2018 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interfering RNA-induced stable inhibition of <i>NRF2</i> in ovarian carcinoma SKOV3 and renal carcinoma A498 reduced the levels of c-MET and EGFR.
|
29291022 |
2017 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment with cabozantinib could increase EGFR and decrease PD-L1 membrane surface expression in RCC cells and enhance the killing ability of CAR-NK-92 cells against the RCC cells <i>in vitro</i>.
|
29423418 |
2017 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-514a-3p is a novel tumor suppressor in ccRCC and potentially functions through EGFR/MAPK/ERK pathway.
|
29312487 |
2017 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma.
|
29050225 |
2017 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway.
|
24192126 |
2013 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the role of EGFR in renal cell carcinoma (RCC), the authors analyzed 1088 tumors in a tissue microarray format by using immunohistochemistry and fluorescence in situ hybridization (FISH).
|
22161775 |
2012 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The activation of epidermal growth factor (EGF) through its receptor, EGFR, is one of the major mechanisms that mediate renal cell carcinoma (RCC) metastasis.
|
22736024 |
2012 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our in vitro investigations revealed that 2HF suppresses VHL-mutant RCC to a significantly greater extent than VHL-wild-type RCC by inhibiting epidermal growth factor receptor signaling, which is increased due to VHL mutations in RCC.
|
21304051 |
2011 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene amplification of EGFR was investigated in a cohort of 315 patients with advanced RCC from a previously reported randomised study.
|
20167476 |
2010 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that mutations in TP53, KRAS, or EGFR are not major contributors to the RCC development even in the absence of VHL inactivation.
|
20137853 |
2010 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report a case of intragenic EGFR microdeletion in renal cell carcinoma (RCC) associated with the effect of treatment by gefitinib.
|
18625569 |
2009 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
|
18243508 |
2008 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since EGFR-MAPK and apoptosis pathways play important roles in renal cell carcinoma survival.
|
18723275 |
2008 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) expression has been associated with clinical outcome in some studies of renal-cell carcinoma (RCC).
|
16052341 |
2006 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we determined if a Her-2/Her-1 inhibitor (PKI-166) can enhance the tumor-suppressive effect of Cx32 in Caki-2 cells from human renal cell carcinoma.
|
15699574 |
2005 |
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data identify EGFR as a critical determinant of HIF-2alpha-dependent tumorigenesis and show at the molecular level that EGFR remains a credible target for therapeutic strategies against VHL-/- renal carcinoma.
|
15958567 |
2005 |
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results from this study do not support the validity of further clinical trials on gefitinib for RCC with genotyping even in Japanese patients, although EGFR plays a key role in tumor progression.
|
16180134 |
2005 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anti-EGFR MAbs have shown antitumor activity in advanced colorectal carcinoma, squamous cell carcinomas of the head and neck, non-small-cell lung cancer (NSCLC) and renal cell carcinomas.
|
15753456 |
2005 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that RCC cell lines expressed EGFR mRNA in the near-absence of other ErbB family members.
|
15956968 |
2005 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor and erbB2 expression in 42 patients with RCC was also evaluated to investigate the correlation with AP-2 isoforms.
|
15245963 |
2004 |
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family.
|
15360049 |
2004 |